Gohibic

Gohibic is a prescription‑only intravenous solution that contains the monoclonal antibody vilobelimab as its active ingredient. Marketed in the European Union, the product is supplied as a sterile solution for infusion. Vilobelimab belongs to the immunomodulator class and works by targeting complement component C5a, thereby modulating inflammatory pathways. The formulation is administered by healthcare professionals in a clinical setting. It is indicated for specific inflammatory conditions under specialist supervision.

Gohibic (vilobelimab) is investigated for use in diseases where complement‑mediated inflammation contributes to pathology.

- Severe COVID‑19 pneumonia requiring hospitalization, where excessive C5a activity is implicated. - Acute respiratory distress syndrome (ARDS) associated with hyperinflammatory responses. - Certain autoimmune disorders characterized by complement activation, such as systemic lupus erythematosus flares. - Experimental treatment protocols for cytokine release syndrome in oncology patients. - Investigational use in transplant‑related inflammatory complications.

The safety profile of Gohibic reflects the pharmacology of complement inhibition and includes both frequent mild reactions and less common serious events.

Common: - Infusion‑related reactions such as flushing, chills, or mild fever. - Headache or dizziness during or shortly after administration. - Nausea or mild gastrointestinal discomfort. - Transient elevation of liver enzymes.

Serious: - Severe hypersensitivity or anaphylaxis. - Increased susceptibility to bacterial infections, particularly encapsulated organisms. - Thrombotic microangiopathy or clotting abnormalities.

Before initiating Gohibic, clinicians should evaluate patient history and monitor for conditions that could be worsened by complement blockade.

- Assess for active or recent serious infections; defer treatment if uncontrolled. - Screen for known hypersensitivity to vilobelimab or any excipients in the formulation. - Evaluate vaccination status, especially against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b. - Monitor complete blood count and liver function tests during therapy. - Use caution in patients with a history of thrombotic events or coagulopathy. - Consider pregnancy and lactation status; limited data are available.

Vilobelimab may interact with other agents that affect immune function or complement pathways.

Avoid: - Concurrent use of other complement inhibitors (e.g., eculizumab) due to overlapping mechanisms. - Live bacterial vaccines administered during treatment, which may have reduced efficacy.

Use with caution: - Immunosuppressive drugs such as high‑dose corticosteroids or cytotoxic agents; infection risk may increase. - Anticoagulants, because of reported clotting abnormalities in rare cases. - Antibiotics targeting encapsulated bacteria; monitor for breakthrough infections. - Concomitant biologics that modulate cytokine activity; assess cumulative immunomodulation.